Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib (Q33387073)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib |
scientific article |
Statements
1 reference
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib (English)
1 reference
G Mickisch
1 reference
M Gore
1 reference
B Escudier
1 reference
S Walzer
1 reference
M Nuijten
1 reference
17 November 2009
1 reference
1 reference
102
1 reference
80-86
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference